Principles of
Antineoplastic
Drug Development
and Pharmacology

edited by
Richard L. Schilsky
Cancer Research Center
University of Chicago
Chicago, Illinois

Gérard A. Milano
Centre Antoine-Lacassagne
Nice, France

Mark J. Ratain
Cancer Research Center
University of Chicago
Chicago, Illinois
Contents

Series Introduction (Bruce D. Cheson) iii  
Preface v  
Contributors xi

Part I. Principles of Drug Development

1. Cancer Drug Screening  
   Michael R. Grever 1

2. The Human Tumor-Cloning Assay  
   Axel-R. Hanauske, Susan G. Hilsenbeck, and Daniel D. Von Hoff 15

3. Phase I Clinical Trial Design  
   Rosemarie Mick 29

   Renzo Canetta 37

5. Development of Biological Agents  
   Rosemary Mazanet, Mary Ann Foote, and George Morstyn 55

Part II. Principles of Antineoplastic Pharmacology

6. Clinical Pharmacology of Anticancer Drugs  
   B. W. Berry and Charles Erlichman 75
Contents

7. Principles of Pharmacokinetics and Pharmacodynamics
   Mark J. Ratain and Rosemarie Mick
   123

8. Biochemical Modulation of Cancer Chemotherapy
   George A. Sotos and Carmen J. Allegra
   143

9. Drug Interactions in Cancer Chemotherapy
   François Lokiec
   189

10. Drug–Radiation Interactions
    Everett E. Vokes
    203

11. Principles of Chemotherapy Interaction with Biological Agents
    Mario Sznol, Christine L. Carter, and Dan L. Longo
    223

12. Hematopoietic Growth Factors and Cancer Chemotherapy
    Michael S. Gordon
    241

13. Dose Intensity
    William M. Hryniuk
    263

Part III. Principles of Chemotherapy Dosing

14. Polymorphic Drug-Metabolizing Enzymes
    Zhihong Lu and Robert B. Diasio
    281

15. Human Cytochromes P-450
    Frank J. Gonzalez
    307

16. Cellular Pharmacodynamics of Anticancer Drugs
    Peter J. O'Dwyer, Thomas C. Hamilton, Kang-Shen Yao, Robert F. Ozols,
    and James M. Gallo
    329

17. Cancer Chemotherapy in the Elderly
    Maurice Schneider
    363

18. Cancer Chemotherapy and Pharmacology in Children
    Steven Weitman and Barton A. Kamen
    375

19. Adaptive Control of Drug Dosage Regimens: Basic Concepts, Relevant Issues,
    and Clinical Applications
    Roger W. Jelliffe
    399

20. Individualized Dosing of Anticancer Drugs
    Alan V. Boddy and A. Hilary Calvert
    435

Part IV. Principles of Drug Resistance

21. Multidrug Resistance
    Ahmad R. Safa
    457
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>22. DNA Topoisomerases and Tumor Cell Resistance to Their Inhibitors</td>
<td>487</td>
</tr>
<tr>
<td>William T. Beck</td>
<td></td>
</tr>
<tr>
<td>23. The Glutathione System and Drug Resistance</td>
<td>503</td>
</tr>
<tr>
<td>Gerald Batist, Robyn L. Schecter, and Moulay A. Alaoui-Jamali</td>
<td></td>
</tr>
<tr>
<td>24. Importance of DNA Repair in Cancer Chemotherapy</td>
<td>523</td>
</tr>
<tr>
<td>M. Eileen Dolan</td>
<td></td>
</tr>
<tr>
<td>25. Resistance to Antimetabolites</td>
<td>543</td>
</tr>
<tr>
<td>Godefridus J. Peters and Gerrit Jansen</td>
<td></td>
</tr>
<tr>
<td>Part V. Principles of Drug Delivery</td>
<td></td>
</tr>
<tr>
<td>26. Targeted Drug Delivery</td>
<td>587</td>
</tr>
<tr>
<td>Pramod K. Gupta, John B. Cannon, and Anil Kumar Tibrewal</td>
<td></td>
</tr>
<tr>
<td>27. Intra-Arterial Chemotherapy</td>
<td>617</td>
</tr>
<tr>
<td>William D. Ensminger</td>
<td></td>
</tr>
<tr>
<td>28. Intraperitoneal Chemotherapy</td>
<td>629</td>
</tr>
<tr>
<td>Maurie Markman</td>
<td></td>
</tr>
<tr>
<td>29. Intrathecal Chemotherapy</td>
<td>641</td>
</tr>
<tr>
<td>Susan M. Blaney and David G. Poplack</td>
<td></td>
</tr>
<tr>
<td>30. Systemic Infusional Chemotherapy</td>
<td>661</td>
</tr>
<tr>
<td>Jacob J. Lokich and Norwood Anderson</td>
<td></td>
</tr>
<tr>
<td>31. Circadian Pharmacodynamics</td>
<td>681</td>
</tr>
<tr>
<td>William J. M. Hrushesky, Robert de W. Marsh, and Patricia A. Wood</td>
<td></td>
</tr>
<tr>
<td>Index</td>
<td>721</td>
</tr>
</tbody>
</table>